Focal adhesion kinase inhibition synergizes with nab-paclitaxel to target pancreatic ductal adenocarcinoma

被引：0
作者：
T. Y. S. Le Large
M. F. Bijlsma
B. El Hassouni
G. Mantini
T. Lagerweij
A. A. Henneman
N. Funel
B. Kok
T. V. Pham
R. de Haas
L. Morelli
J. C. Knol
S. R. Piersma
G. Kazemier
H. W. M. van Laarhoven
E. Giovannetti
C. R. Jimenez
机构：
[1] VU University Amsterdam,Department of Surgery, Cancer Center Amsterdam, Amsterdam University Medical Centers
[2] VU University,Department of Medical Oncology, Cancer Center Amsterdam, Amsterdam University Medical Centers
[3] University of Amsterdam,Laboratory for Experimental Oncology and Radiobiology, Cancer Center Amsterdam, Amsterdam University Medical Center
[4] VU University,OncoProteomics Laboratory, Department of Medical Oncology, Cancer, Cancer Center Amsterdam, Amsterdam University Medical Centers
[5] Oncode Institute,Cancer Pharmacology Lab, AIRC
[6] Fondazione Pisana per la Scienza,Start
[7] VU University Amsterdam,Up
[8] Azienda Ospedaliero-Universitaria Pisana,Department of Neurosurgery, Cancer Center Amsterdam, Amsterdam University Medical Centers
[9] University of Amsterdam,Department of Medical Oncology, Cancer Center Amsterdam, Amsterdam University Medical Center
来源：
Journal of Experimental & Clinical Cancer Research | / 40卷
关键词：
Pancreatic cancer; Therapy; FAK; EPHA2; MET; Phosphoproteomics;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 50 条
  • [41] Gemcitabine plus nab-paclitaxel for pancreatic cancer and interstitial lung disease: A nationwide longitudinal study
    Saito, Kei
    Michihata, Nobuaki
    Hamada, Tsuyoshi
    Jo, Taisuke
    Matsui, Hiroki
    Fushimi, Kiyohide
    Nakai, Yousuke
    Yasunaga, Hideo
    Fujishiro, Mitsuhiro
    CANCER SCIENCE, 2023, 114 (10) : 3996 - 4005
  • [42] Phase I Study of Preoperative Chemoradiotherapy Using Gemcitabine Plus Nab-Paclitaxel for Patients Who Have Localized Pancreatic Ductal Adenocarcinoma With Contact or Invasion to Major Arteries
    Hayasaki, Aoi
    Kishiwada, Masashi
    Murata, Yasuhiro
    Komatsubara, Haruna
    Nakagawa, Yuki
    Maeda, Koki
    Shinkai, Toru
    Noguchi, Daisuke
    Gyoten, Kazuyuki
    Fujii, Takehiro
    Iizawa, Yusuke
    Tanemura, Akihiro
    Kuriyama, Naohisa
    Sakurai, Hiroyuki
    Isaji, Shuji
    Mizuno, Shugo
    PANCREAS, 2021, 50 (08) : 1230 - 1235
  • [43] Phase 1 trial of enzalutamide in combination with gemcitabine and nab-paclitaxel for the treatment of advanced pancreatic cancer
    Mahipal, Amit
    Tella, Sri Harsha
    Kommalapati, Anuhya
    Goyal, Gaurav
    Soares, Heloisa
    Neuger, Anthony
    Copolla, Domenico
    Kim, Jongphil
    Kim, Richard
    INVESTIGATIONAL NEW DRUGS, 2019, 37 (03) : 473 - 481
  • [44] Neoadjuvant Nab-paclitaxel and Gemcitabine in Borderline Resectable or Locally Advanced Unresectable Pancreatic Adenocarcinoma in Patients Who Are Ineligible for FOLFIRINOX
    Peterson, Shawn L.
    Husnain, Muhammad
    Pollack, Terri
    Pimentel, Agustin
    Loaiza-Bonilla, Arturo
    Westendorf-Overley, Colleen
    Ratermann, Kelley
    Anthony, Lowell
    Desimone, Philip
    Goel, Gaurav
    Kudrimoti, Mahesh
    Dineen, Sean
    Tzeng, Ching-Wei D.
    Hosein, Peter J.
    ANTICANCER RESEARCH, 2018, 38 (07) : 4035 - 4039
  • [45] Phase I Study of Chemoradiation Therapy (nab-Paclitaxel/Gemcitabine) in 18 Patients with Unresectable Locally Advanced Pancreatic Adenocarcinoma
    Ioka, Tatsuya
    Katayama, Kazuhiro
    Hibino, Kenji
    Yutaro, Abe
    Tamura, Takeshi
    Takada, Ryoji
    Fukutake, Nobuyasu
    Ashida, Reiko
    Ohkawa, Kazuyoshi
    Akita, Hiroshi
    Takahashi, Hidenori
    Hirata, Takero
    Teshima, Teruki
    JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2015, 30 : 147 - 147
  • [46] Nab-paclitaxel plus S-1 versus nab-paclitaxel plus gemcitabine in patients with advanced pancreatic cancer: a multicenter, randomized, phase II study
    Jin, Min
    Liu, Hong-Li
    Xue, Jun
    Ma, Hong
    Liu, Jun-Li
    Lin, Zhen-Yu
    Wang, Jing
    Bao, Le-Qun
    Luo, Zhi-Guo
    Yu, Xiong-Jie
    Li, Shuang
    Hu, Jian-Li
    Zhang, Tao
    ONCOLOGIST, 2024, 29 (10) : e1406 - e1418
  • [47] Efficacy and toxicity comparison of nab-paclitaxel plus S-1 and nab-paclitaxel plus gemcitabine as first-line chemotherapy for metastatic pancreatic cancer
    Guo Xi
    Xu Yaolin
    Ji Yuan
    Fan Yue
    Wang Dansong
    Jin Dayong
    Zhuang Rongyuan
    Wu Lili
    Lou Wenhui
    Zhou Yuhong
    Department of Medical Oncology
    Department of General Surgery
    Department of Pathology
    Department of Traditional Chinese Medicine
    Department of Radiotherapy
    胰腺病学杂志（英文）, 2020, 03 (01) : 35 - 41
  • [48] A Phase 1/1B Trial of ADI-PEG 20 Plus Nab-Paclitaxel and Gemcitabine in Patients With Advanced Pancreatic Adenocarcinoma
    Lowery, Maeve A.
    Yu, Kenneth H.
    Kelsen, David Paul
    Harding, James J.
    Bomalaski, John S.
    Glassman, Danielle C.
    Covington, Christina M.
    Brenner, Robin
    Hollywood, Ellen
    Barba, Adalberto
    Johnston, Amanda
    Liu, Kay Chia-Wei
    Feng, Xiaoxing
    Capanu, Marinela
    Abou-Alfa, Ghassan K.
    O'Reilly, Eileen M.
    CANCER, 2017, 123 (23) : 4556 - 4565
  • [49] Comparison of efficacy and toxicity of FOLFIRINOX and gemcitabine with nab-paclitaxel in unresectable pancreatic cancer
    Muranaka, Tetsuhito
    Kuwatani, Masaki
    Komatsu, Yoshito
    Sawada, Kentaro
    Nakatsumi, Hiroshi
    Kawamoto, Yasuyuki
    Yuki, Satoshi
    Kubota, Yoshimasa
    Kubo, Kimitoshi
    Kawahata, Shuhei
    Kawakubo, Kazumichi
    Kawakami, Hiroshi
    Sakamoto, Naoya
    JOURNAL OF GASTROINTESTINAL ONCOLOGY, 2017, 8 (03) : 566 - 571
  • [50] A phase I trial of nab-paclitaxel, gemcitabine, and capecitabine for metastatic pancreatic cancer
    Andrew H. Ko
    Thach-Giao Truong
    Emily Kantoff
    Kimberly A. Jones
    Elizabeth Dito
    Anna Ong
    Margaret A. Tempero
    Cancer Chemotherapy and Pharmacology, 2012, 70 : 875 - 881
12345